← All trials
NCT05881265
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2023
- Primary completion
- Jan 1, 2025
- Completion date
- Jan 1, 2026
- First posted
- May 31, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiao Tong UniversityLead sponsor
- Jiao Tong UniversityReponsible party - principal investigator
- Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU)Collaborator
- Zhaxin HospitalStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.